Stonegate Capital Partners Updates Coverage on Cingulate Inc. Following FDA Complete Response Letter
Cingulate Inc. faces a CMC-driven resubmission process for CTx-1301 after FDA issues Complete Response Letter, but strong cash position and intact product thesis suggest timeline rather than viability is the key concern.
Stonegate Capital Partners has updated its coverage on Cingulate Inc. (NASDAQ: CING) in a new report released today. The update follows the company's recent announcement regarding the FDA's Complete Response Letter (CRL) for its lead candidate CTx-1301, shifting the near-term focus from a PDUFA-driven approval event to a Chemistry, Manufacturing, and Controls (CMC)-driven resubmission process.
According to the report, the FDA's CRL focused on specific CMC information requests, with no clinical safety or efficacy concerns identified. Stonegate views this as a timing issue rather than a product viability concern, as the path forward depends on completing the requested CMC work, resubmitting to the FDA, and moving through the next review cycle. The core product thesis remains intact based on the information disclosed.
Importantly, Cingulate disclosed nearly $30 million of cash on hand, which management believes is sufficient to address the FDA's requests, execute the resubmission process, and continue pre-commercial activities into 2027. This financial cushion provides a runway for the company to navigate the regulatory process without immediate capital pressure.
Stonegate's report highlights the key takeaways: the balance sheet now supports execution, with C$51.1 million in cash and C$51.0 million of equity, funding the company's advance without near-term capital pressure. The CMC work is moving from concept to execution, with capital being deployed directly into addressing the FDA's requests. The report also notes that the uplisting to the TSXV on May 29, 2026 improves investability and market visibility, which should help institutional access as the story matures.
For the full announcement, including downloadable images and bios, click here.
Stonegate Capital Partners is a leading capital markets advisory firm providing investor relations, equity research, and institutional investor outreach services for public companies. Its affiliate, Stonegate Capital Markets (member FINRA), provides a full spectrum of investment banking services for public and private companies.